Merck Profit Margin 2010-2024 | MRK

Current and historical gross margin, operating margin and net profit margin for Merck (MRK) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Merck net profit margin as of September 30, 2024 is 19.23%.
Merck Annual Profit Margins
Merck Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $242.036B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $715.765B 74.14
Novo Nordisk (NVO) Denmark $361.560B 26.07
Johnson & Johnson (JNJ) United States $349.755B 14.54
AbbVie (ABBV) United States $299.000B 15.74
Roche Holding AG (RHHBY) Switzerland $241.405B 0.00
AstraZeneca (AZN) United Kingdom $211.494B 18.00
Novartis AG (NVS) Switzerland $200.659B 13.34
Pfizer (PFE) United States $147.398B 10.08
Sanofi (SNY) $130.724B 11.84
Bayer (BAYRY) Germany $21.574B 3.45
Innoviva (INVA) United States $1.160B 9.65